+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 99Years
All Genders
ID07684144

Long-term Extension Study Evaluating Maridebart Cafraglutide for Adults With Obesity or Overweight and Type 2 Diabetes Mellitus

Led by Amgen · Updated on 2026-10-05

950

Participants Needed

45

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the long-term effects of maridebart cafraglutide in adults with obesity or overweight who also have type 2 diabetes. This Phase 3 trial aims to evaluate how well the drug works, its safety, and how well participants tolerate it over time. The trial is an extension of a previous study, allowing continued assessment of the treatments impact over a longer period. Participants receive different doses of maridebart cafraglutide or placebo, administered as injections under the skin. Those who had low doses in the previous study continue with the same low dose every 4 weeks. Participants who had medium or high doses in the earlier trial may be randomly assigned to continue their dose every 4 or 8 weeks, or receive placebo injections every 4 weeks. Some participants who previously received placebo will start a high dose with a gradual increase before reaching the full dose. During the study, participants will have regular visits for up to 48 weeks to monitor body weight changes, blood sugar control, waist size, and quality of life. Researchers will carefully track any side effects or serious health events throughout the treatment. The study runs until March 2028, providing detailed information on the long-term use of maridebart cafraglutide.

CONDITIONS

Brief Title

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Research Team

A

Amgen Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here